A pivotal moment is unfolding in Britain as a man spearheading a campaign to assist infants affected by spinal muscular atrophy (SMA) emphasizes the urgency for action. Giles Lomax, whose seven-year-old twins Finn and Zara battle SMA, a muscle-wasting disease, is advocating for universal newborn testing, supported by Health Secretary Wes Streeting’s efforts to push the UK National Screening Committee for consideration.
Giles and his wife Becky, residing in Edinburgh, learned about their twins’ Type 2 SMA diagnosis when they were 15 months old. The disease can be addressed with three NHS treatments that aim to correct the faulty gene or supply a substitute protein to prevent muscle degeneration, constituting a potential cure if administered promptly at birth.
Following his children’s diagnosis, Giles assumed the role of CEO at SMA UK, a charity dedicated to promoting research and aiding families impacted by SMA. In a recent piece for the Mirror, Giles reflects on the prolonged advocacy journey and stresses the necessity for the long-awaited change in SMA screening protocols.
SMA UK has persistently campaigned over the past decade for SMA inclusion in the newborn screening heel prick test. Notably, in 2018, the UK National Screening Committee initially rejected SMA for national screening due to insufficient evidence on treatments for presymptomatic infants. However, advancements in therapies like nusinersen, risdiplam, and Zolgensma gene therapy have revolutionized outcomes for SMA patients since then.
The overwhelming evidence now supports early identification and treatment of infants before symptoms manifest, enabling previously unimaginable milestones to be achieved. Families recount the anguish of witnessing their child’s physical decline while awaiting delayed diagnoses, emphasizing the critical importance of timely intervention for SMA patients.
The UK stands at a crucial juncture with the UK NSC revisiting its 2018 decision and moving towards an in-service evaluation of newborn SMA screening. Scotland’s initiation of SMA screening represents a significant milestone, yet the necessity for nationwide implementation remains vital to ensure equitable access to early detection and treatment.
The imperative for effective screening and treatment is undeniable, with every infant deserving a fair chance at a healthy start in life. Accelerating and expanding screening efforts are imperative to prevent further delays in addressing SMA cases, as every moment is critical for these vulnerable infants, shaping their futures permanently.
